Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 15,621 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin and Connective Tissue Disease Clear all

Conditions: Hair Thinning
Interventions: XVIE; Other
Lead sponsor: Restore Biologics Holdings, Inc. dba Xtressé; Industry
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Maitland, Florida • Marriottsville, Maryland

Conditions: Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis
Interventions: Robotic Arm Assisted Total Knee Arthroplasty; Device
Lead sponsor: MAKO Surgical Corp.; Industry
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: St. Helena, California • Tampa, Florida • Houston, Texas

Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions: Not listed
Lead sponsor: xCures; Industry
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Atopic Dermatitis
Interventions: LY3375880, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Fountain Valley, California • Los Angeles, California • Northridge, California + 11 more

Conditions: Melanoma
Interventions: GSK2118436, GSK1120212; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Metastases, Adult
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Sarah Sammons, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lupus Erythematosus, Systemic
Interventions: GDC-0853; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Los Alamitos, California • Boca Raton, Florida • Brandon, Florida + 7 more

Conditions: Chronic Disease, HIV/AIDS, Liver Diseases, Inflammatory Bowel Diseases, Cardiovascular Diseases, Rheumatic Diseases, Neurodegenerative Diseases
Interventions: Non-interventional (observational only); Other
Lead sponsor: Epividian; Industry
Eligibility: 0 Years and older
Enrollment: 2,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2035
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma
Interventions: interleukin-12; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: 1997 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Paclitaxel, BKM120 matching placebo, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 21
States / cities: Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more

Conditions: Psoriasis
Interventions: CP-690,550, Placebo Vehicle; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Irvine, California • San Diego, California • Chicago, Illinois + 9 more

Conditions: Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Tubular Ductal Breast Carcinoma
Interventions: accelerated partial breast irradiation, intensity-modulated radiation therapy, image-guided radiation therapy, therapeutic conventional surgery; Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lupus Nephritis
Interventions: Pentoxifylline, Placebos; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Metastatic Melanoma
Interventions: Cisplatin, Docetaxel, Temodar; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: Spincare matrix; Device
Lead sponsor: Stanford University; Other
Eligibility: 6 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Breast Cancer
Interventions: Cost Discussion; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Melanoma, Skin Cancer
Interventions: Panobinostat, Ipilimumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Osteogenesis Imperfecta
Interventions: AGA2115, Placebo; Drug
Lead sponsor: Angitia Incorporated Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Lake Forest, California

Conditions: Herpes Simplex
Interventions: Acyclovir, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 28 Days
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Rheumatoid Arthritis
Interventions: Rozibafusp Alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Anniston, Alabama • Duncansville, Pennsylvania • Dallas, Texas

Conditions: Stress, Cognitive Change, Breast Cancer, Breast Carcinoma, Breast Neoplasm, Cognitive Dysfunction
Interventions: Mobile Daily Diary; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: The-Optimal-Lymph-Flow (TOLF) Program; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus Cream 1%; Drug
Lead sponsor: Novartis; Industry
Eligibility: 3 Months and older
Timeline: 2004 – 2005
U.S. locations: 0
States / cities: Not listed

Search by objective public record fields.

Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair

Robotic Arm Assisted Total Knee Arthroplasty

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Neoadjuvant Immunotherapy in Brain Metastases

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Observational Pharmaco-Epidemiology Research & Analysis

Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Topical CP-690,550 For Chronic Plaque Psoriasis

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer

Pentoxifylline in Lupus Nephritis

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients

Understanding and Addressing Patient and Provider Preferences Around Discussions of Cost of Breast Cancer Care

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates

Multiple Ascending Doses of Rozibafusp Alfa (AMG 570) in Adults With Rheumatoid Arthritis

Surviving Daily Life

Healthy ME: Advancing Health Equity in Lymphatic Pain and Lymphedema in Black and Hispanic Women With Breast Cancer

Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis